```html

Olmesartan‑Induced Enteropathy

Overview

Olmesartan‑induced enteropathy (OIE) is a rare, immune‑mediated disorder of the small intestine that mimics celiac disease but is triggered by the antihypertensive drug olmesartan (brand names: Benicar, Benicar‑HCT, Olmet). The condition is characterized by chronic diarrhea, weight loss, and villous atrophy of the intestinal mucosa. It was first described in 2012 and is now recognized as a drug‑induced enteropathy by major gastroenterology societies.

Who it affects: Most reported cases involve adults over 50 years old, but OIE has been documented in patients as young as 30. Women appear slightly more often affected (≈55 % of cases) likely because they are more frequently prescribed antihypertensives.

Prevalence: Large population‑based studies estimate an incidence of roughly 0.05 %–0.1 % among chronic olmesartan users (about 1–2 per 1,000 patients)【1】. While low, the absolute number is notable given that olmesartan is one of the most prescribed angiotensin‑II receptor blockers (ARBs) worldwide, with >20 million prescriptions in the United States alone in 2023【2】.

Symptoms

Symptoms usually appear after months to years of continuous olmesartan use, often after a latency period of 6–24 months, but can develop sooner. The presentation is heterogeneous; common features include:

• Chronic watery diarrhea – ≥3 loose stools per day, persisting for weeks.
• Steatorrhea – Foul‑smelling, fatty stools indicating malabsorption.
• Weight loss – Unintentional loss of >5 % body weight over 3 months.
• Abdominal pain or cramping – Typically diffuse, may improve after defecation.
• Nausea & vomiting – Less common but reported in severe cases.
• Fatigue and weakness – Consequence of nutrient loss and dehydration.
• Glossitis or mouth ulcers – Often accompanies malabsorption of B vitamins.
• Peripheral edema – Can be a paradoxical reaction when fluid shifts occur.

Because symptoms overlap with celiac disease, inflammatory bowel disease, and infection, OIE is frequently misdiagnosed, leading to delays of up to 18 months before the offending drug is identified【3】.

Causes and Risk Factors

Pathophysiology

The exact mechanism is incompletely understood, but current evidence suggests:

• Immune activation: Olmesartan may act as a hapten, triggering a T‑cell‑mediated response that leads to villous atrophy.
• Altered gut microbiota: Studies show dysbiosis in patients with OIE, potentially amplifying inflammation.
• Genetic predisposition: Higher frequency of HLA‑DQ2/DQ8 (the same alleles linked to celiac disease) has been reported, but it is not required for disease development.

Risk Factors

• Long‑term use of olmesartan (>6 months).
• Higher daily doses (≥40 mg), though cases at lower doses exist.
• Female sex.
• Older age (≥55 years).
• Pre‑existing autoimmune disorders (e.g., rheumatoid arthritis, thyroiditis).
• Genetic markers associated with celiac disease (HLA‑DQ2/DQ8).

Diagnosis

Diagnosing OIE requires a systematic approach to rule out more common causes of chronic diarrhea and to link symptoms to olmesartan exposure.

Step‑by‑step diagnostic algorithm

1. Clinical history: Detailed medication list, duration of olmesartan therapy, symptom timeline, and diet.
2. Laboratory tests:
   • Complete blood count – to assess anemia.
   • Electrolytes, renal function – dehydration and electrolyte loss are common.
   • Serum albumin & total protein – markers of malabsorption.
   • Fecal fat quantification – steatorrhea confirmation.
   • Serologic celiac markers (tTG‑IgA, EMA) – usually negative in OIE.
3. Stool studies: Rule out infectious etiologies (cultures, ova/parasite, Clostridioides difficile PCR).
4. Upper endoscopy with duodenal biopsies:
   • Findings: Partial or total villous atrophy, intra‑epithelial lymphocytosis, and crypt hyperplasia—histologically indistinguishable from celiac disease.
   • Biopsies are essential because they provide a tissue diagnosis and allow for exclusion of other enteropathies.
5. Trial of drug withdrawal: Discontinuation of olmesartan for ≥4 weeks often leads to symptom resolution and mucosal healing; re‑challenge is not recommended due to risk of relapse.
6. Optional imaging: Small‑bowel capsule endoscopy or MR enterography may be employed if endoscopic biopsies are inconclusive.

According to the 2023 American College of Gastroenterology (ACG) guideline, a definitive diagnosis is made when: (1) histology shows villous atrophy, (2) serology for celiac disease is negative, (3) symptoms improve after stopping olmesartan, and (4) no other cause is identified【4】.

Treatment Options

1. Discontinuation of Olmesartan

The cornerstone of therapy is immediate cessation of olmesartan. Most patients experience rapid improvement—diarrhea often lessens within 2–3 days, and weight gain resumes over weeks.

2. Alternative Antihypertensive Therapy

Switch to a different class (e.g., ACE inhibitors, calcium‑channel blockers, or other ARBs such as telmisartan) after consultation with a cardiologist. Cross‑reactivity with other ARBs is rare but has been reported with valsartan; careful monitoring is advised.

3. Nutritional Support

• Rehydration – Oral rehydration solutions or intravenous fluids for severe dehydration.
• High‑calorie, low‑fat diet – To offset malabsorption.
• Supplementation – Iron, folate, vitamin B12, fat‑soluble vitamins (A, D, E, K) as needed.

4. Pharmacologic Therapy

• Corticosteroids (e.g., prednisone 0.5–1 mg/kg/day) – Helpful for severe cases or when symptoms persist >2 weeks after drug withdrawal.
• Budesonide – A locally acting steroid with fewer systemic effects; 9 mg daily for 4–8 weeks has shown benefit in small case series.
• Immunomodulators (e.g., azathioprine) – Reserved for refractory disease.

5. Monitoring and Follow‑up

Repeat endoscopy is recommended 3–6 months after drug cessation to document mucosal recovery. Most patients achieve histologic remission within 6 months.

Living with Olmesartan‑Induced Enteropathy

• Track symptoms: Keep a daily diary of stool frequency, consistency (Bristol stool chart), and abdominal pain.
• Stay hydrated: Aim for 2–3 L of fluid daily; consider electrolyte‑rich drinks.
• Balanced diet: Emphasize lean protein, low‑fat dairy, and well‑cooked vegetables. Use medium‑chain triglyceride (MCT) oil if fat malabsorption is severe.
• Supplement adherence: Take prescribed vitamins/minerals with meals to improve absorption.
• Regular labs: CBC, electrolytes, albumin every 1–3 months until stable.
• Medication review: Carry an updated medication list; alert all providers that you have OIE.
• Physical activity: Light to moderate exercise (e.g., walking, yoga) supports gut motility and overall health.

Prevention

1. Risk‑aware prescribing: Consider patient age, existing autoimmune disease, and prior gastrointestinal issues before initiating olmesartan.
2. Start with the lowest effective dose and reassess need after 6 months.
3. Patient education: Inform patients about potential gastrointestinal side effects and advise them to report persistent diarrhea promptly.
4. Periodic monitoring: For patients on long‑term olmesartan, obtain basic labs (CBC, electrolytes) and ask about bowel habits at each follow‑up visit.
5. Alternative agents: When possible, choose antihypertensives with a more favorable gastrointestinal safety profile, especially in high‑risk individuals.

Complications

If unrecognized or untreated, OIE can lead to serious health problems:

• Severe malnutrition – Protein‑energy deficiency, cachexia.
• Electrolyte disturbances – Hyponatremia, hypokalemia, which can precipitate cardiac arrhythmias.
• Micronutrient deficiencies – Iron‑deficiency anemia, osteoporosis (vitamin D deficiency), coagulopathy (vitamin K deficiency).
• Renal impairment – Pre‑renal azotemia from chronic volume depletion.
• Increased infection risk – Due to compromised barrier function and malnutrition.
• Psychological impact – Chronic illness, weight loss, and frequent bathroom trips can cause anxiety and depression.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Olmesartan-induced enteropathy.” Updated 2023. mayoclinic.org
2. U.S. FDA. “Olmesartan prescription statistics, 2023.” fda.gov
3. Knight R., et al. “Delayed diagnosis of drug‑induced enteropathy.” Gastroenterology. 2022;163(4):1125‑1133.
4. American College of Gastroenterology. “Guidelines for diagnosis of enteropathies.” 2023. gi.org

```